BeStock  
Stocks › TARS

Tarsus Pharmaceuticals TARS

US equityMarket cap rank #2378
$74.46 +$1.46 (+1.99%)
Market closed · Oct 5, 10:20 pm ET · Last extended-hours $74.46 0.00%
Open$73.22
Prev close$73.00
Day range$72.76 – $75.00
Volume939.6K
Market cap$3.48B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±7.4%last 12 reports
Closed higher6 of 1250% of the time
Best reaction+15.2%
Worst reaction-9.3%

Stock move on the day after each report

+12.2%2023/Q3-3.4%2023/Q4-8.9%2024/Q1+13.7%2024/Q2+0.3%2024/Q3-9.3%2024/Q4-5.8%2025/Q1+15.2%2025/Q2-4.6%2025/Q3+7.8%2025/Q4-1.2%2026/Q1+6.6%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q26 Aug 2026Pre Market±11.3%+6.59%Within range
2026/Q16 May 2026After Market±13.5%-1.24%Within range
2025/Q423 Feb 2026After Market±14.7%+7.79%Within range
2025/Q34 Nov 2025After Market±12.9%-4.62%Within range
2025/Q26 Aug 2025After Market±17.3%+15.15%Within range
2025/Q11 May 2025After Market±14.7%-5.84%Within range
2024/Q425 Feb 2025Pre Market±17.0%-9.33%Within range
2024/Q313 Nov 2024After Market±23.3%+0.31%Within range
2024/Q28 Aug 2024After Market±16.5%+13.72%Within range
2024/Q18 May 2024After Market±18.6%-8.86%Within range
2023/Q427 Feb 2024None±14.9%-3.44%Within range
2023/Q39 Nov 2023After Market–+12.20%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q2, ended Jun 2026

Revenue$173.91M+69.4% YoY
Operating profit-$19.91M+10.3% YoY
Net profit-$18.55M+8.8% YoY
Diluted EPS-$0.43+10.4% YoY

Revenue, last 8 quarters

$48.1MSep '24$66.4MDec '24$78.3MMar '25$102.7MJun '25$118.7MSep '25$151.7MDec '25$162.1MMar '26$173.9MJun '26

Net profit, last 8 quarters

$-23.4MSep '24$-23.1MDec '24$-25.1MMar '25$-20.3MJun '25$-12.6MSep '25$-8.4MDec '25$-7.0MMar '26$-18.6MJun '26

Profitability & balance sheet

Gross margin93.0%
Operating margin-11.4%
Net margin-10.7%

Discussion

No comments yet — be the first to weigh in on TARS.

Leave a comment

Scroll to Top